Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2019 Filed Feb 4, 2019 23:51 UTC |
Xie H ErinPortfolio Manager
|
Exercise / conversionPhantom Shares · Derivative | 2,820.15 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-007082 · doc4.xml · derivative · entry 4 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,640.31 Underlying: Common Stock · 2,820.15 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_date: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.expiration_date: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 23:51 UTC |
Xie H ErinPortfolio Manager
|
GrantPhantom Shares · Derivative | 19,051.93 | $39.67 | $755,790.06 |
DisclosureSEC source: 0001209191-19-007082 · doc4.xml · derivative · entry 3 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,051.93 Underlying: Common Stock · 19,051.93 shares Expires not disclosed F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F4 · derivative.exercise_price: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F4 · derivative.exercise_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F4 · derivative.expiration_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 23:51 UTC |
Xie H ErinPortfolio Manager
|
Disposition to issuerCommon Stock | 4,363.71 | $39.67 | $173,108.38 |
DisclosureSEC source: 0001209191-19-007082 · doc4.xml · nonDerivative · entry 2 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F3 · price: As previously reported on a Form 4 dated February 2, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 23:51 UTC |
Xie H ErinPortfolio Manager
|
Exercise / conversionCommon Stock | 4,363.71 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-007082 · doc4.xml · nonDerivative · entry 1 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,363.71 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F3 · price: As previously reported on a Form 4 dated February 2, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 23:22 UTC |
Accettella ChristopherPortfolio Manager
|
Exercise / conversionPhantom Shares · Derivative | 82.96 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-006967 · doc4.xml · derivative · entry 4 Accettella Christopher · CIK 0001513197 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165.92 Underlying: Common Stock · 82.96 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_date: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.expiration_date: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 23:22 UTC |
Accettella ChristopherPortfolio Manager
|
GrantPhantom Shares · Derivative | 197.6 | $39.67 | $7,838.79 |
DisclosureSEC source: 0001209191-19-006967 · doc4.xml · derivative · entry 3 Accettella Christopher · CIK 0001513197 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197.6 Underlying: Common Stock · 197.6 shares Expires not disclosed F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F3 · derivative.exercise_price: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F3 · derivative.exercise_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F3 · derivative.expiration_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 23:22 UTC |
Accettella ChristopherPortfolio Manager
|
Disposition to issuerCommon Stock | 82.96 | $39.67 | $3,291.02 |
DisclosureSEC source: 0001209191-19-006967 · doc4.xml · nonDerivative · entry 2 Accettella Christopher · CIK 0001513197 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576.98 F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 23:22 UTC |
Accettella ChristopherPortfolio Manager
|
Exercise / conversionCommon Stock | 82.96 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-006967 · doc4.xml · nonDerivative · entry 1 Accettella Christopher · CIK 0001513197 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659.94 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated February 2, 2018, the Reporting Person was granted phantom shares on January 31, 2018 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:23 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 109.19 | $41.25 | $4,504.09 |
DisclosureSEC source: 0001209191-18-055247 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,690.55 Underlying: Common Stock · 109.19 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:30 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 32.08 | $41.25 | $1,323.30 |
DisclosureSEC source: 0001209191-18-055265 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342.65 Underlying: Common Stock · 32.08 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:39 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 16.64 | $41.25 | $686.40 |
DisclosureSEC source: 0001209191-18-055281 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618.68 Underlying: Common Stock · 16.64 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:35 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 49.73 | $41.25 | $2,051.36 |
DisclosureSEC source: 0001209191-18-055273 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474.23 Underlying: Common Stock · 49.73 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 12:16 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 74.59 | $41.25 | $3,076.84 |
DisclosureSEC source: 0001209191-18-055237 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,782.88 Underlying: Common Stock · 74.59 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 16:26 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 125.33 | $41.25 | $5,169.86 |
DisclosureSEC source: 0001209191-18-055256 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941.31 Underlying: Common Stock · 125.33 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 09:26 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 109.34 | $41.17 | $4,501.53 |
DisclosureSEC source: 0001209191-18-042728 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,557.46 Underlying: Common Stock · 109.34 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 13:33 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 32.13 | $41.17 | $1,322.79 |
DisclosureSEC source: 0001209191-18-042744 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290.76 Underlying: Common Stock · 32.13 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 09:39 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 16.67 | $41.17 | $686.30 |
DisclosureSEC source: 0001209191-18-042755 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592.94 Underlying: Common Stock · 16.67 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 09:37 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 49.8 | $41.17 | $2,050.27 |
DisclosureSEC source: 0001209191-18-042752 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418.09 Underlying: Common Stock · 49.8 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 09:21 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 74.7 | $41.17 | $3,075.40 |
DisclosureSEC source: 0001209191-18-042720 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,682.46 Underlying: Common Stock · 74.7 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 13:29 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 125.5 | $41.17 | $5,166.84 |
DisclosureSEC source: 0001209191-18-042736 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,773.42 Underlying: Common Stock · 125.5 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 09:23 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 130.37 | $34.52 | $4,500.37 |
DisclosureSEC source: 0001209191-18-025077 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,424.18 Underlying: Common Stock · 130.37 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 13:29 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 38.31 | $34.52 | $1,322.46 |
DisclosureSEC source: 0001209191-18-025093 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,237.82 Underlying: Common Stock · 38.31 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 09:35 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 19.87 | $34.52 | $685.91 |
DisclosureSEC source: 0001209191-18-025109 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566.74 Underlying: Common Stock · 19.87 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 09:32 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 59.38 | $34.52 | $2,049.80 |
DisclosureSEC source: 0001209191-18-025101 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362.2 Underlying: Common Stock · 59.38 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 09:20 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 89.07 | $34.52 | $3,074.70 |
DisclosureSEC source: 0001209191-18-025069 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,581.18 Underlying: Common Stock · 89.07 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 13:26 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 149.65 | $34.52 | $5,165.92 |
DisclosureSEC source: 0001209191-18-025085 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604.13 Underlying: Common Stock · 149.65 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 16:28 UTC |
McClements KylePortfolio Manager
|
GrantPhantom Shares · Derivative | 916.4 | $36.21 | $33,182.84 |
DisclosureSEC source: 0001209191-18-006880 · doc4.xml · derivative · entry 1 McClements Kyle · CIK 0001320768 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916.4 Underlying: Common Stock · 916.4 shares Expires not disclosed F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_price: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.expiration_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:34 UTC |
Xie H ErinPortfolio Manager
|
Exercise / conversionPhantom Shares · Derivative | 1,449.59 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-007091 · doc4.xml · derivative · entry 4 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,899.04 Underlying: Common Stock · 1,449.59 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_price: As previously reported on a Form 4 dated March 27, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated March 27, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_date: As previously reported on a Form 4 dated March 27, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.expiration_date: As previously reported on a Form 4 dated March 27, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:34 UTC |
Xie H ErinPortfolio Manager
|
GrantPhantom Shares · Derivative | 7,945.67 | $36.21 | $287,712.71 |
DisclosureSEC source: 0001209191-18-007091 · doc4.xml · derivative · entry 3 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,945.67 Underlying: Common Stock · 7,945.67 shares Expires not disclosed F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F3 · derivative.exercise_price: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F3 · derivative.exercise_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F3 · derivative.expiration_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:34 UTC |
Xie H ErinPortfolio Manager
|
Disposition to issuerCommon Stock | 1,449.59 | $36.21 | $52,489.65 |
DisclosureSEC source: 0001209191-18-007091 · doc4.xml · nonDerivative · entry 2 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated March 27, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:34 UTC |
Xie H ErinPortfolio Manager
|
Exercise / conversionCommon Stock | 1,449.59 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-007091 · doc4.xml · nonDerivative · entry 1 Xie H Erin · CIK 0001320932 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,449.59 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · price: As previously reported on a Form 4 dated March 27, 2017, the Reporting Person was granted phantom shares on January 31, 2017 payable in cash on vesting, which occurs in equal installments on each of the first three anniversaries of the grant date. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 21:08 UTC |
Accettella ChristopherPortfolio Manager
|
GrantPhantom Shares · Derivative | 233.95 | $36.21 | $8,471.33 |
DisclosureSEC source: 0001209191-18-006805 · doc4.xml · derivative · entry 1 Accettella Christopher · CIK 0001513197 · Portfolio Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233.95 Underlying: Common Stock · 233.95 shares Expires not disclosed F1 · derivative.exercise_price: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_price: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.exercise_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.exercise_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. F1 · derivative.expiration_date: A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash. F2 · derivative.expiration_date: These phantom shares vest in equal installments on each of the first three anniversaries of the award. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 09:06 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 123.02 | $36.59 | $4,501.30 |
DisclosureSEC source: 0001209191-18-003725 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,271.8 Underlying: Common Stock · 123.02 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 14:15 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 36.15 | $36.59 | $1,322.73 |
DisclosureSEC source: 0001209191-18-003741 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,179.1 Underlying: Common Stock · 36.15 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 09:25 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 18.75 | $36.59 | $686.06 |
DisclosureSEC source: 0001209191-18-003758 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537.57 Underlying: Common Stock · 18.75 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 09:20 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 56.03 | $36.59 | $2,050.14 |
DisclosureSEC source: 0001209191-18-003750 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297.67 Underlying: Common Stock · 56.03 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 09:01 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 84.05 | $36.59 | $3,075.39 |
DisclosureSEC source: 0001209191-18-003717 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466.73 Underlying: Common Stock · 84.05 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 14:10 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 141.21 | $36.59 | $5,166.87 |
DisclosureSEC source: 0001209191-18-003733 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412.72 Underlying: Common Stock · 141.21 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 11:47 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 92.87 | $36.70 | $3,408.33 |
DisclosureSEC source: 0001209191-17-057083 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,129.7 Underlying: Common Stock · 92.87 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 15:55 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 36.02 | $36.70 | $1,321.93 |
DisclosureSEC source: 0001209191-17-057107 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123.97 Underlying: Common Stock · 36.02 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 12:00 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 37.37 | $36.70 | $1,371.48 |
DisclosureSEC source: 0001209191-17-057123 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510.2 Underlying: Common Stock · 37.37 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 11:57 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 55.83 | $36.70 | $2,048.96 |
DisclosureSEC source: 0001209191-17-057115 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237.62 Underlying: Common Stock · 55.83 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 11:42 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 83.75 | $36.70 | $3,073.63 |
DisclosureSEC source: 0001209191-17-057074 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,359.71 Underlying: Common Stock · 83.75 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 15:52 UTC |
HUBBARD ROBERT GLENNDirector
|
GrantPerformance Rights · Derivative | 140.71 | $36.70 | $5,164.06 |
DisclosureSEC source: 0001209191-17-057099 · doc4.xml · derivative · entry 1 HUBBARD ROBERT GLENN · CIK 0001283051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,233.79 Underlying: Common Stock · 140.71 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 15:49 UTC |
Harris Jerrold BDirector
|
GrantPerformance Rights · Derivative | 151.97 | $36.70 | $5,577.30 |
DisclosureSEC source: 0001209191-17-057091 · doc4.xml · derivative · entry 1 Harris Jerrold B · CIK 0001333739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,372.77 Underlying: Common Stock · 151.97 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 11:17 UTC |
CAVANAGH RICHARDDirector
|
GrantPerformance Rights · Derivative | 91.63 | $37.19 | $3,407.72 |
DisclosureSEC source: 0001209191-17-045424 · doc4.xml · derivative · entry 1 CAVANAGH RICHARD · CIK 0001075522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019.45 Underlying: Common Stock · 91.63 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 15:27 UTC |
KESTER W CARLDirector
|
GrantPerformance Rights · Derivative | 35.54 | $37.19 | $1,321.73 |
DisclosureSEC source: 0001209191-17-045448 · doc4.xml · derivative · entry 1 KESTER W CARL · CIK 0001141904 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069.72 Underlying: Common Stock · 35.54 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 11:35 UTC |
ROBARDS KAREN PDirector
|
GrantPerformance Rights · Derivative | 36.87 | $37.19 | $1,371.20 |
DisclosureSEC source: 0001209191-17-045464 · doc4.xml · derivative · entry 1 ROBARDS KAREN P · CIK 0001141903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464.9 Underlying: Common Stock · 36.87 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 11:31 UTC |
Lynch Catherine A.Director
|
GrantPerformance Rights · Derivative | 55.09 | $37.19 | $2,048.80 |
DisclosureSEC source: 0001209191-17-045456 · doc4.xml · derivative · entry 1 Lynch Catherine A. · CIK 0001668396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178.74 Underlying: Common Stock · 55.09 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 11:14 UTC |
Castellano Michael JDirector
|
GrantPerformance Rights · Derivative | 82.63 | $37.19 | $3,073.01 |
DisclosureSEC source: 0001209191-17-045416 · doc4.xml · derivative · entry 1 Castellano Michael J · CIK 0001326138 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254.58 Underlying: Common Stock · 82.63 shares Expires not disclosed F1 · security: The Performance Rights were accrued under the BlackRock Deferred Compensation Plan. F2 · derivative.exercise_price: One Performance Right is convertible into the cash value of one share of BlackRock Health Sciences Trust. F3 · derivative.exercise_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. F3 · derivative.expiration_date: The Performance Rights are to be settled 100% in cash at the deferral period chosen by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.